NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.

Reverse

In its latest success in getting price concessions from drug makers, the National Institute for Health and Care Excellence (NICE) says it is now backing Perjeta (pertuzumab) to treat a certain form of breast cancer on the National Health Service in England and Wales after vendor Roche offered a confidential discount.

The HTA's decision endorsing the drug's use in combination with Herceptin (trastuzumab) and the chemotherapy docetaxel as an option before...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip